Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Erlonat-150 Erlotinib Tablets IP 150mg:
Introducing Erlonat-150, a specialized cancer therapy containing 150 mg of Erlotinib, formulated to target and treat non-small cell lung cancer (NSCLC) and pancreatic cancer effectively.
Uses of Erlonat-150 Erlotinib Tablets IP 150mg:
Erlonat-150 Tablets are used for:
Treating non-small cell lung cancer (NSCLC) with EGFR mutations
Managing locally advanced, unresectable, or metastatic pancreatic cancer
Providing a targeted therapy option for improved cancer treatment outcomes
Benefits of Erlonat-150 Erlotinib Tablets IP 150mg:
Targeted action against EGFR-mutant cancer cells
Effective in reducing tumor size and inhibiting cancer progression
Enhances survival rates and quality of life in cancer patients
Convenient oral administration for patient compliance
Mechanism of Action of Erlonat-150 Erlotinib Tablets IP 150mg:
Erlotinib, the active component of Erlonat-150, works by inhibiting the epidermal growth factor receptor (EGFR) tyrosine kinase. This inhibition blocks the EGFR signaling pathway, which is essential for cancer cell proliferation and survival. By preventing these signals, Erlotinib effectively reduces cancer cell growth and promotes cancer cell death, leading to tumor shrinkage and slower disease progression.